Methylated B-vitamin supplement
Methylated B-Complex
Methylated B-complex is listed with a 6-hour half-life in the app; no half-life for the blend itself was identified in PubMed, ClinicalTrials.gov or DailyMed.
Methylated B-Complex after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.
Drawn from the half-life in the app's model, ~6 h. The model's figures
- Compound
- Methylated B-Complex
- Symbol
- BCX
- Family
- Supplements
- Parts
- 14
- References
- 14
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
The app lists methylated B-complex as a vitamin supplement taken by mouth, one tablet a day. The app's notes name methyl-B12, methylfolate (5-MTHF), P-5-P and methylcobalamin as its ingredients. The trials of a blend described below combined L-methylfolate, methylcobalamin and pyridoxal-5'-phosphate, in different amounts in each trial.1,2 A ClinicalTrials.gov search for the three ingredients returned five entries, of which two were randomised, placebo-controlled trials of the blend; the other three (a 20-person study, an administrative claims analysis and a support programme) were not reviewed.
A DailyMed search for the blend returned no labels, and a search for "L-methylfolate" returned two labels for one single-ingredient tablet, which the label describes as a medical food.3 The app grades the evidence for methylated B-complex as strong. The registry entries name Pamlab, Inc. as lead sponsor of the Metanx trial and S.LAB (SOLOWAYS) as lead sponsor of the Soloways trial.4,2
How it works
Pokushalov and colleagues (Nutrients, 2024) write in their introduction that "Methylfolate, a bioactive form of folate, directly contributes to the remethylation of homocysteine to methionine".5 They describe pyridoxal-5'-phosphate as having "a pivotal role in the trans-sulfuration pathway, where homocysteine is converted into cysteine".5 They describe methylcobalamin as "another essential cofactor in the remethylation of homocysteine to methionine".5 These are statements of background in the paper's introduction; the trial's primary endpoint was the percent change in homocysteine levels, not a measurement of the pathways.5
Prinz-Langenohl and colleagues (British Journal of Pharmacology, 2009) state that "The 677C→T mutation of MTHFR reduces the activity of this enzyme".6 In their crossover study of 24 healthy women given single doses, they conclude that "[6S]-5-MTHF increases plasma folate more effectively than FA irrespective of the 677C→T mutation of the MTHFR".6 The app's notes state that methylated forms bypass an MTHFR conversion step that about 40% of the population struggles with; none of the sources read gives that proportion. The L-methylfolate calcium label states that the product "is indicated regardless of MTHFR C677T polymorphism genotype", within its listed uses as adjunctive support in major depressive disorder and in schizophrenia.3
Watanabe (Experimental Biology and Medicine, 2007) writes that the intrinsic factor-mediated system "is estimated to be saturated at about 1.5-2.0 microg per meal under physiologic conditions".7 The PubMed record of that review does not mention methylcobalamin, so it describes dietary vitamin B12 in general, not methylcobalamin supplements.
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~6 h
- Bioavailability
- 60%
- Typical dose
- 1 tablet/day
- Route
- Oral
- Time to peak
- ~2 h
Sources in this part
The table sets the app's figures beside what the sources report; the sources report single folate doses and B12 in general, not the blend.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~6 h | No half-life for the blend was reported in the sources read; the app's notes give about 3 to 5 hours for the folate fraction and about 6 days circulating for B12, with no reference |
| Time to peak | ~2 h | In 24 healthy women, mean time to maximum of 33.3 min (TT genotype) and 36.9 min (CC genotype) after a single 416 µg dose of [6S]-5-MTHF; in 13 men after 500 µg of [6S]-5-MTHF, peaks "typically" between 0.5 and 3 h6,8 |
| Bioavailability | 60% | No absolute figure for the blend was reported. Relative to folic acid, the area under the curve of [6S]-5-MTHF was 200.95% (TT) and 159.2% (CC) in women;6 short-term bioavailabilities were "equivalent" in men;8 US and Japanese reference intakes assume 50% of dietary B12 is absorbed7 |
In the Prinz-Langenohl crossover study, plasma folate AUC and Cmax "were significantly higher, and tmax significantly shorter for [6S]-5-MTHF compared with FA in both genotypes".6 Unmetabolised folic acid appeared in plasma in 18 of 24 women after folic acid and in 2 of 24 after [6S]-5-MTHF.6 Pentieva and colleagues (Journal of Nutrition, 2004) reached a different conclusion in 13 men: the maximum plasma folate response was 33.4 ± 3.9 nmol/L after folic acid and 31.8 ± 3.9 nmol/L after [6S]-5-MTHF (P = 0.7).8 Prinz-Langenohl and colleagues note that Pentieva and colleagues "used the FA presaturation model, which could alter the folate-binding protein capacities".6 Neither record reports an elimination half-life.6,8
Human studies
The first two rows are trials of the blend itself; later rows are trials of single components or of folic acid, B6 and B12 combinations, and are not results for the blend.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Fonseca and colleagues, Am J Med 20131 | Multicentre, randomised, double-blind, placebo-controlled; lead sponsor Pamlab, Inc. per the registry1,4 | 214 patients with type 2 diabetes and neuropathy, baseline vibration perception threshold 25-45 volts1 | L-methylfolate calcium 3 mg, methylcobalamin 2 mg and pyridoxal-5'-phosphate 35 mg, or placebo; 24 weeks1 | No significant effect on vibration perception threshold (primary); NTSS-6 improved at week 16 (P=.013) and week 24 (P=.033); homocysteine fell 2.7±3.0 μmol/L against a rise of 0.5±2.4 (P=.0001); no single adverse event in 2% or more of subjects1 |
| Pokushalov and colleagues, Nutrients 20245 | Randomised, double-blind, parallel-group, placebo-controlled; supplements made by S.Lab (Soloways), registry lead sponsor S.LAB (SOLOWAYS)5,2 | 54 enrolled and 51 completed; aged 40 to 75, homocysteine above 15 µmol/L, at least one minor allele in MTHFR, MTR or MTRR5 | L-methylfolate 1 mg, P5P 50 mg and methylcobalamin 500 mcg per capsule, 2 capsules a day, or placebo; 180 days5 | Homocysteine 30.0% lower with the blend and 1.8% higher with placebo; LDL-C 7.5% lower against 2.6% higher; total cholesterol, HDL-C, triglycerides and hsCRP differences not significant; adverse event counts not given in the text5 |
| Lonn and colleagues (HOPE-2), N Engl J Med 20069 | Randomised, placebo-controlled; component study of folic acid with B6 and B12, not a methylated blend9 | 5522 patients aged 55 or older with vascular disease or diabetes9 | 2.5 mg folic acid, 50 mg vitamin B6 and 1 mg vitamin B12 daily, or placebo; average of five years9 | Primary composite outcome in 519 (18.8%) against 547 (19.8%), relative risk 0.95 (95% CI 0.84 to 1.07; P=0.41); stroke relative risk 0.75 (0.59 to 0.97); hospitalisation for unstable angina relative risk 1.24 (1.04 to 1.49)9 |
| Bostom and colleagues, Circulation 200010 | Block-randomised comparison of L-5-methyltetrahydrofolate with folic acid; component study10 | 50 stable hemodialysis patients10 | 17 mg L-5-methyltetrahydrofolate or 15 mg folic acid daily, each with 50 mg B6 and 1.0 mg B12; 12 weeks10 | Total homocysteine fell 17.0% (95% CI 12.0% to 22.0%) with the methylated folate and 14.8% (9.6% to 20.1%) with folic acid, P=0.444; 2 of 25 against 0 of 25 reached normalisation (P=0.490)10 |
| Prinz-Langenohl and colleagues, Br J Pharmacol 20096 | Randomised crossover pharmacokinetic study of one folate component; funded by Merck Selbstmedikation GmbH6 | 24 healthy women (16 TT, 8 CC for MTHFR 677C to T)6 | Single oral doses of 400 µg folic acid and 416 µg [6S]-5-MTHF; plasma sampled to 8 h6 | AUC 21.4 against 10.8 nM (TT) and 19.2 against 11.9 nM (CC) favouring [6S]-5-MTHF; shorter tmax; unmetabolised folic acid in 18 of 24 after folic acid6 |
| Pentieva and colleagues, J Nutr 20048 | Double-blind crossover of one folate component8 | 13 men presaturated with folic acid8 | Single 500 µg doses of folic acid and [6S]-5-MTHF, and placebo, at 1-week intervals8 | Maximum plasma folate 33.4 ± 3.9 against 31.8 ± 3.9 nmol/L (P = 0.7); the authors call the short-term bioavailabilities equivalent8 |
| Papakostas and colleagues, J Clin Psychiatry 201411 | Post hoc analysis of a randomised, double-blind, placebo-controlled sequential parallel comparison trial; component study11 | 75 outpatients with SSRI-resistant major depressive disorder11 | L-methylfolate 15 mg a day for 60 days, placebo for 30 days then L-methylfolate for 30 days, or placebo for 60 days11 | Patients with specific biological and genetic markers had significantly greater pooled mean change on the HDRS-28 with L-methylfolate than placebo; the authors write "Confirmatory studies are needed"11 |
| Martí-Carvajal and colleagues, Cochrane Database Syst Rev 201712 | Systematic review and meta-analysis of randomised trials of B6, B9 or B12 given alone or in combination12 | 15 trials, 71,422 participants; follow-up one to 7.3 years12 | Homocysteine-lowering vitamins against placebo or comparator12 | Myocardial infarction RR 1.02 (95% CI 0.95 to 1.10); death from any cause RR 1.01 (0.96 to 1.06); serious adverse events RR 1.07 (1.00 to 1.14); stroke RR 0.90 (0.82 to 0.99)12 |
Deeper analysis: the Metanx trial in diabetic neuropathy
Fonseca and colleagues (Tulane University Health Sciences Center and other sites, American Journal of Medicine, 2013) tested a combination of L-methylfolate, methylcobalamin and pyridoxal-5'-phosphate in 214 patients with type 2 diabetes and neuropathy.1 The primary end point was vibration perception threshold, and the record states "There was no significant effect on VPT".1 The authors report that "Improvement in NTSS scores was related to baseline MMA and inversely related to baseline PLP and metformin use".1 The registry lists mean NTSS-6 change from baseline of -0.09 (SD 1.42) with Metanx and -0.40 (SD 1.72) with placebo at week 16, and -0.96 (SD 1.54) against -0.53 (SD 1.69) at week 24, with P=0.013 and P=0.033 from a mixed models analysis.4 Their stated limitation is that "the trial duration may have been too short to show an effect on VPT", and they add that "further research on the effects in patients with cobalamin deficiency would be useful".1 They conclude that the combination "appears to be a safe and effective therapy for alleviation of peripheral neuropathy symptoms, at least in the short term".1 The registry entry lists Pamlab, Inc. as lead sponsor and describes the active arm as "Metanx one tablet twice a day".4 The registry also records a restrictive agreement, stating that "Investigators agreed to delay publication of study results until after multi-center results were published or, a period of up to 20 months had elapsed after termination of the study, whichever shall occur first".4 The PubMed record carries no funding statement or author disclosures, so the authors' ties to the sponsor could not be checked.1 The registry reports serious adverse events in 5 of 106 participants on Metanx and 8 of 108 on placebo, and other adverse events in 25 of 106 and 27 of 108.4 Of 373 patients screened, 214 entered the study and 200 completed it, with 99 of 106 completing on Metanx and 101 of 108 on placebo.4 Among the serious events listed, a transient ischemic attack was recorded in 2 participants on Metanx and none on placebo, congestive cardiac failure in 1 on Metanx and none on placebo, and death in none on Metanx and 2 on placebo.4
Deeper analysis: the Soloways trial in people with MTHFR, MTR and MTRR variants
Pokushalov and colleagues (Nutrients, 2024) randomised 54 people aged 40 to 75 with homocysteine above 15 µmol/L and at least one minor allele in MTHFR, MTR or MTRR to a methylfolate, P5P and methylcobalamin capsule or placebo for 180 days.5 Fifty-one completed it, and the tables report 26 people on the blend and 25 on placebo.5 The methods describe an intention-to-treat analysis of participants with at least one post-baseline efficacy evaluation.5 At six months the blend group "experienced a notable mean reduction in homocysteine levels of 30.0% (95% CI: −39.7% to −20.3%)", and the difference from placebo was "significant at 31.8% (95% CI: −46.5% to −15.5%".5 Among secondary outcomes, LDL-C fell 7.5% on the blend against a 2.6% rise on placebo, whereas total cholesterol "did not reach statistical significance (p = 0.08)" and hsCRP showed "no significant difference between the two groups (p = 0.23)".5 In the prespecified subgroups, homocysteine fell 48.3% in homozygous minor allele carriers and 18.6% in mixed allele carriers.5 The subgroup sizes differ within the paper: the text gives 18 and 33 participants, while the subgroup table headings give 10 and 16.5 The authors write that "the limited sample size precludes definitive conclusions" for baseline comparisons in the homozygous group.5 Their stated limitations are "a small sample size, sufficient for homocysteine and LDL-C level analysis, but restrictive for broader genetic analysis, and a six-month duration".5 The paper's text reports no adverse event or discontinuation counts.5 On funding, the paper's funding statement says S.Lab (SOLOWAYS) "contributed solely by manufacturing the supplements used in the research", while its acknowledgments thank the company for "generous support in funding this research".5 The conflict-of-interest statement says four authors "were employed by the company Scientific Research Laboratory, Triangel Scientific", which the registry lists as an industry collaborator.5,2
Deeper analysis: B vitamins and cardiovascular outcomes (components, not the blend)
Lonn and colleagues (Population Health Research Institute, McMaster University, New England Journal of Medicine, 2006) gave 5522 patients with vascular disease or diabetes folic acid, B6 and B12, and the combination lowered homocysteine by 2.4 micromol per liter while placebo raised it by 0.8.9 The authors conclude that "Supplements combining folic acid and vitamins B6 and B12 did not reduce the risk of major cardiovascular events in patients with vascular disease".9 The PubMed record lists the publication type as "Research Support, Non-U.S. Gov't" without a funding or disclosure statement, so the sponsor and author ties were not checked.9 The Cochrane review by Martí-Carvajal and colleagues (2017) included randomised trials with follow-up of one year or longer and excluded studies in patients with end-stage renal disease.12 The review lists support from the Iberoamerican Cochrane Centre and the Cochrane Heart Group and states that one author was employed by Eli Lilly (2004) and by Merck (2007) to run workshops "not related to his work with Cochrane or any Cochrane review".12 Bostom and colleagues (Circulation, 2000) conclude that "high-dose oral L-5-methyltetrahydrofolate-based supplementation does not afford improved tHcy-lowering efficacy in hemodialysis patients" relative to high-dose folic acid.10
Deeper analysis: the single-dose folate studies
Prinz-Langenohl and colleagues compared a single oral dose of folic acid and [6S]-5-MTHF in 16 women with the TT genotype and 8 with the CC genotype, and the study was funded by Merck Selbstmedikation GmbH.6 They state that "None of the authors had any personal or financial conflicts of interest with the sponsoring institution".6 Their stated limitation is that the method "only describes the appearance and clearance of total plasma folate" and that it "is not clear whether the increase in plasma folate is derived from the oral dose itself or induced by tissue redistribution".6 The PubMed record of the Pentieva study does not state a funding source.8
Doses reported in studies and on labels
| Source | Preparation | Amounts reported | Setting and length |
|---|---|---|---|
| App's figure | Methylated B-complex tablet | 1 tablet a day | Oral |
| Metanx trial, Fonseca 2013 and registry NCT007267131,4 | L-methylfolate calcium, methylcobalamin, pyridoxal-5'-phosphate | 3 mg, 2 mg and 35 mg; the registry describes one tablet twice a day | 214 patients with type 2 diabetes and neuropathy; 24 weeks |
| Soloways trial, Pokushalov 20245 | L-methylfolate, P5P, methylcobalamin | 1 mg, 50 mg and 500 mcg per capsule; 2 capsules a day | 54 people with MTHFR, MTR or MTRR variants; 180 days |
| L-methylfolate calcium tablet label, medical food3 | L-methylfolate calcium alone, 7.5 mg and 15 mg tablets | "The usual adult dose is 7.5mg to 15mg given daily with or without food or as directed under medical supervision" | Label uses: adjunctive use in major depressive disorder and in schizophrenia |
| Papakostas 201411 | L-methylfolate alone | 15 mg a day | 75 outpatients with SSRI-resistant depression; 60 days |
Side effects reported
In the Metanx trial the authors write that "Adverse events were infrequent, with no single event occurring in ≥2% of subjects".1 The registry for that trial reports serious adverse events in 5 of 106 participants on Metanx and 8 of 108 on placebo, including 2 transient ischemic attacks on Metanx and none on placebo, and 2 deaths on placebo and none on Metanx.4 The Soloways paper's text gives no adverse event counts.5 In HOPE-2, more patients on folic acid, B6 and B12 than on placebo were hospitalised for unstable angina, with a relative risk of 1.24.9 The L-methylfolate calcium label states that "Allergic reactions have been reported following the use of oral L-METHYLFOLATE CALCIUM Tablets" and lists a contraindication in "patients with known hypersensitivity to any of the components contained in this product".3 The same label says the product "may be less likely than folic acid to mask vitamin B12 deficiency" and that "Folate therapy alone is inadequate for the treatment of a B12 deficiency".3 Its interaction list says metformin treatment in patients with type 2 diabetes decreases serum folate.3 Muhamad and colleagues (Nutrients, 2023), in a systematic review of 20 articles on vitamin B6 and neuropathy, write that higher B6 levels, "which usually occur following the taking of nutritional supplements, may lead to the development of a predominantly, if not exclusively, sensory neuropathy of the axonal type".13 The same review states that B6 supplementation "has not been proven harmful at permitted daily doses in patients who already suffer from PN", and that the available studies "have had small sample sizes".13
Bloodwork and markers
The app lists homocysteine, serum B12 and red blood cell folate as the markers to monitor. Homocysteine was the primary endpoint of the Soloways trial and a secondary end point of the Metanx trial.5,1 In the hemodialysis trial, final on-treatment total homocysteine was 20.0 micromol/L with L-5-methyltetrahydrofolate and 19.5 micromol/L with folic acid.10 The Metanx trial also measured methylmalonic acid, and improvement in symptom scores was related to baseline levels of it.1 The L-methylfolate label describes its use for people with "suboptimal" levels "in the cerebrospinal fluid, plasma, and/or red blood cells" who have major depressive disorder.3
Regulatory and anti-doping status
Sources in this part
The DailyMed search for a blend label returned none, and the single L-methylfolate label found states that it "is a medical food dispensed by prescription" and "is not an Orange Book product".3 The label defines medical foods as "intended for a patient who has a limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients".3 The Soloways registry entry lists its intervention type as DIETARY_SUPPLEMENT, and its oversight fields mark the study as not an FDA-regulated drug study and not an FDA-regulated device study.2 The text of the WADA Prohibited List 2026 retrieved for this review contains none of the terms cobalamin, folate, folic, pyridoxal, pyridoxine, B12 or B6.14
Storage and handling
Sources in this part
What is not known
No half-life for the blend was identified in PubMed, ClinicalTrials.gov or DailyMed, and none of the sources read gives the app's 6 hours. No absolute oral bioavailability for the blend was identified; the app lists 60%. The two blend trials studied different populations (type 2 diabetes with neuropathy, and people with MTHFR, MTR or MTRR variants and raised homocysteine), used different amounts, and have not been repeated by other groups in the records identified.1,5 One PubMed query for randomised trials of methylcobalamin versus cyanocobalamin in vitamin B12 deficiency returned one record, the placebo-controlled Metanx trial, so that query returned no randomised comparison of a methylated with a non-methylated B vitamin on clinical outcomes. The trials of the blend measured blood markers and symptom scores; none of the sources read reports a cardiovascular event outcome for a methylated blend, and the cardiovascular trials above used folic acid, B6 and B12.9,12 The app's notes give a circulating period of about 6 days for B12 and a folate half-life of about 3 to 5 hours; none of the sources read states either figure.
Frequently asked questions
What is the half-life of methylated B-complex?
The app lists a half-life of about 6 hours for methylated B-complex. No half-life for the blend was reported in the sources read, so none of the sources read gives a figure to set beside the app's.
How long does methylated B-complex take to reach its peak?
The app lists about 2 hours to peak. In women given one 416 µg dose of [6S]-5-MTHF alone, the mean time to maximum plasma folate was 33.3 minutes (TT genotype) and 36.9 minutes (CC genotype).6 In men given 500 µg of [6S]-5-MTHF, peaks "typically occurred in individuals between 0.5 and 3 h postprandially".8
Is methylated B-complex banned by WADA?
The text of the WADA Prohibited List 2026 retrieved for this review does not contain the terms cobalamin, folate, folic, pyridoxal, pyridoxine, B12 or B6.14
Is methylated B-complex approved by the FDA?
No DailyMed label for a methylated B-complex blend was identified. The one L-methylfolate calcium label identified describes a medical food dispensed by prescription, for adjunctive use in major depressive disorder and in schizophrenia.3
Does a methylated B-complex lower homocysteine?
In the Soloways trial, homocysteine fell 30.0% with the blend and rose 1.8% with placebo over 180 days; 54 people with MTHFR, MTR or MTRR variants were enrolled and the tables report 26 on the blend and 25 on placebo.5 In the Metanx trial, homocysteine decreased by 2.7±3.0 μmol/L against a rise of 0.5±2.4 μmol/L with placebo over 24 weeks in 214 patients with type 2 diabetes and neuropathy.1
Did the Metanx blend improve neuropathy in its trial?
Do B vitamins that lower homocysteine change heart attack risk?
Is 5-MTHF absorbed better than folic acid?
Guides, tools and comparisons
References
- Fonseca VA, et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med 2013. PMID 23218892
- S.LAB (SOLOWAYS). Evaluating the Impact of B Vitamin Supplementation (Soloways) on Homocysteine and LDL-C Levels in Patients With MTHFR, MTR, and MTRR Polymorphisms. ClinicalTrials.gov NCT06163443. NCT06163443
- Bryant Ranch Prepack. L-Methylfolate Calcium (levomefolate calcium) tablets, medical food label. DailyMed record, version 101, 2026. DailyMed label
- Pamlab, Inc. Study of Metanx in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN). ClinicalTrials.gov NCT00726713. NCT00726713
- Pokushalov E, et al. Effect of Methylfolate, Pyridoxal-5'-Phosphate, and Methylcobalamin (Soloways) Supplementation on Homocysteine and Low-Density Lipoprotein Cholesterol Levels in Patients with MTHFR, MTR and MTRR Polymorphisms: A Randomized Controlled Trial. Nutrients 2024. PMID 38892484
- Prinz-Langenohl R, et al. [6S]-5-methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild-type 677C to T polymorphism of methylenetetrahydrofolate reductase. Br J Pharmacol 2009. PMID 19917061
- Watanabe F. Vitamin B12 sources and bioavailability. Exp Biol Med (Maywood) 2007. PMID 17959839
- Pentieva K, et al. The short-term bioavailabilities of [6S]-5-methyltetrahydrofolate and folic acid are equivalent in men. J Nutr 2004. PMID 14988450
- Lonn E, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006. PMID 16531613
- Bostom AG, et al. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation 2000. PMID 10859289
- Papakostas GI, et al. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry 2014. PMID 24813065
- Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2017. PMID 28816346
- Muhamad R, Akrivaki A, Papagiannopoulou G, Zavridis P, Zis P. The Role of Vitamin B6 in Peripheral Neuropathy: A Systematic Review. Nutrients 2023. PMID 37447150
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list